Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomaterials forum "blueprint" to be developed by FDA/NIH/industry/academic committee.

This article was originally published in The Gray Sheet

Executive Summary

BIOMATERIALS FORUM "BLUEPRINT" TO BE DEVELOPED by a four-person planning committee appointed at a March 28 meeting of FDA's Science Board. The committee, to be chaired by Bernie Liebler, director, technology and regulatory affairs, Health Industry Manufacturers Association, will develop a plan for the HIMA-proposed forum, which will likely consist of one or more gatherings of representatives from industry, academia, FDA and other governmental agencies who will consider FDA's handling of new biomaterials in medical products.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel